Sartorius Stedim Biotech S.A. (0RG8) fair value: what the stock is really worth
As of Jul 17, 2026: fair value of Sartorius Stedim Biotech S.A. €102, price €186, upside -45.3%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sartorius Stedim Biotech S.A. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range €142.54 – €536.86 · fair‑value band €64.94 – €132.06 · the €185.60 price screens above the €101.58 fair value. Dashed = 300-day average. As of Sep 29, 2026.
Follow Sartorius Stedim Biotech in your weekly email
Every Wednesday you see whether Sartorius Stedim Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide.
Show more
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Stock analysis
Sartorius Stedim Biotech S.A. (0RG8) currently trades at €185.60, while our model-based Fair Value estimate is €101.58, 45.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €64.47 per share, and 0 of the 25 models we run sit above the €185.60 price.
Bear case: the Economic Profit group reads lowest at €16.39, and 25 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: €64.94 (bear) to €132.06 (bull), the price of €185.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sartorius Stedim Biotech S.A. reported revenue of €1.9B in FY2020 versus €1.1B in FY2016, a compound +16.1%/yr. Reported net income was €358M in FY2020, compounding +23.5%/yr from FY2016.
Key figures
Market cap €36.3B · P/S ratio 12.1 · Dividend yield 0.4% · Net margin 18.7% · Return on equity 7.1% · Return on assets (EBIT) 17.4% · Operating margin 20.1% · Revenue (TTM) €3.0B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 20% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −44% fair-value upside, at −45%, 0RG8 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (€5.01 to €89.92). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear €64.94Fair Value €101.58Bull €132.06
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+32.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.9%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
21.5% (2016) → 24.7% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Compare Sartorius Stedim Biotech S.A. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Machinery” was too small, so the broader sector is used.)Industrials · 5266 stocks
Beats the sector median on 4/11 measures
Overall it trails its sector peers.
Valuation
Quality Score60 · Above median
Fair Value upside−45.3% · Below median
Profitability
Return on equity (TTM)7.1% · Below median
Return on assets4.4% · Above median
Net margin (TTM)9.7% · Above median
Operating margin (TTM)20.1% · Top 25%
Growth and dividend
Revenue growth2.8% · Below median
Dividend yield (TTM)0.4% · Bottom 25%
Balance sheet
Debt / equity0.35× · Above median
Valuation Multiplesvs Industrials median · lower = cheaper
P/B27.97× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)13.59× · Priciest 25%
EV/EBITDA50.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)14· sector 35
PAST (return on equity)28· sector 29
HEALTH (low debt)82· sector 94
DIVIDEND (yield)7· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sartorius Stedim Biotech S.A. (0RG8) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of €101.58 versus the last price from Jul 17, 2026 of €185.60, about −45% upside (overvalued).
What is the fair value of 0RG8?
Our model-based fair value for Sartorius Stedim Biotech S.A. is €101.58 (as of Sep 29, 2026), built from audited fundamentals. Last price (from Jul 17, 2026): €185.60.
What is the quality score of 0RG8?
Sartorius Stedim Biotech S.A. has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sartorius Stedim Biotech S.A. (0RG8)?
Our model-based price target is the fair value of €101.58 (as of Sep 29, 2026) from 25 valuation models. Cautious scenario €64.94, optimistic scenario €132.06. It is a calculation from audited fundamentals, not an analyst target.
What is the Sartorius Stedim Biotech S.A. stock forecast for 2026?
Our models put fair value at €101.58, about −45% upside versus the last price from Jul 17, 2026 of €185.60 (overvalued). Cautious scenario €64.94, optimistic scenario €132.06. The calculation is refreshed regularly with new filings.
What is the revenue of Sartorius Stedim Biotech S.A. (0RG8)?
Sartorius Stedim Biotech S.A. reported trailing-twelve-month revenue of about €3.0B (latest available figure, as of Sep 29, 2026).
Does Sartorius Stedim Biotech S.A. pay a dividend?
Sartorius Stedim Biotech S.A. currently shows a dividend yield of about 0.37% relative to its recent price (as of Sep 29, 2026).
What is the intrinsic value of Sartorius Stedim Biotech S.A. (0RG8)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sartorius Stedim Biotech S.A. it is €101.58 per share (as of Sep 29, 2026), against a price of €185.60. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Sartorius Stedim Biotech S.A. stock overvalued or undervalued in 2026?
As of Sep 29, 2026, 0RG8 trades above its calculated fair value: price €185.60, fair value €101.58, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RG8?
No. The price is what the market pays today (€185.60); the fair value is what the company's own numbers justify (€101.58). For Sartorius Stedim Biotech S.A. the two are €84.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sartorius Stedim Biotech S.A. worth?
The market values Sartorius Stedim Biotech S.A. at about €36.3B (market capitalisation, as of Sep 29, 2026). Per share that is €185.60; our models calculate a fair value of €101.58 per share.
What do the bullish and bearish scenarios say about 0RG8?
Our models span a range for Sartorius Stedim Biotech S.A.: cautious scenario €64.94, base €101.58, optimistic €132.06 per share (as of Sep 29, 2026, price €185.60). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sartorius Stedim Biotech S.A. (0RG8)?
Balance-sheet figures for Sartorius Stedim Biotech S.A. (as of Sep 29, 2026): return on equity 7.1%, debt of 0.35 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 0RG8 from its 52-week high?
Sartorius Stedim Biotech S.A. trades at €185.60, about 16% below its 52-week high of €220.80 and 20% above the low of €155.25 (as of Jul 17, 2026). Distance from the high says nothing about value: that is what the fair value of €101.58 is for.
Which stocks are comparable to Sartorius Stedim Biotech S.A.?
From the same area (Industrials) we also value CHEMTECH, INLCM, Contemporary Amperex Technology Co, Delta Electronics (Thailand) Public Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sartorius Stedim Biotech S.A. stock attractive at the current price?
The data as of Sep 29, 2026: price €185.60, calculated fair value €101.58 (−45%), Quality Score 60/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RG8 calculated?
We run Sartorius Stedim Biotech S.A. through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €101.58, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sartorius Stedim Biotech S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sartorius Stedim Biotech S.A. (0RG8)?
The latest price we hold is from Jul 17, 2026 and stands at €185.60. Our model-based fair value is €101.58, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sartorius Stedim Biotech S.A. right now?
The price sits above even our optimistic bull case (€132.06). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€64.94 to €132.06) leaves room in how you read the outcome.
Key figures of Sartorius Stedim Biotech S.A.
How large is the market capitalisation of Sartorius Stedim Biotech S.A. (0RG8)?
The market capitalisation of Sartorius Stedim Biotech S.A. is €36.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sartorius Stedim Biotech S.A. (0RG8)?
The price-to-sales ratio of Sartorius Stedim Biotech S.A. is 12.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Sartorius Stedim Biotech S.A. (0RG8)?
The dividend yield of Sartorius Stedim Biotech S.A. is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sartorius Stedim Biotech S.A. (0RG8)?
The net margin of Sartorius Stedim Biotech S.A. is 18.7% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sartorius Stedim Biotech S.A. (0RG8)?
The return on equity (ROE) of Sartorius Stedim Biotech S.A. is 7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sartorius Stedim Biotech S.A. (0RG8)?
On an EBIT basis the return on assets of Sartorius Stedim Biotech S.A. is 17.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sartorius Stedim Biotech S.A. (0RG8)?
The operating margin of Sartorius Stedim Biotech S.A. is 20.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sartorius Stedim Biotech S.A. (0RG8)?
Revenue at Sartorius Stedim Biotech S.A. is growing +2.8% versus a year earlier (3y avg +20.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sartorius Stedim Biotech S.A. (0RG8)?
Earnings per share at Sartorius Stedim Biotech S.A. are growing +37.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Sartorius Stedim Biotech S.A. in the live analysis
One click puts Sartorius Stedim Biotech S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
